OncoMatch/Clinical Trials/NCT07219576
Retifanlimab and Ruxolitinib In Solid Malignancies
Is NCT07219576 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including Ruxolitinib and Retifanlimab for non small cell lung carcinoma.
Treatment: Ruxolitinib · Retifanlimab — The goal of this clinical trial is to learn what dose of ruxolitinib can be given safely together with retifanlimab in patients with metastatic renal cell carcinoma and non-small cell lung carcinoma. The main question it aims to answer is: What is the maximum dose of ruxolitinib that can be used safely in patients with metastatic renal cell carcinoma and non-small cell lung carcinoma, and will it work? Participants will: Take drug ruxolitinib twice a day and keep a diary of when they take ruxolitinib at home; visit the clinic for infusions of retifanlimab every 4 weeks; visit the clinic for checkups and tests.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Cancer type
Non-Small Cell Lung Carcinoma
Renal Cell Carcinoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: anti-PD-1 therapy
having progressed on prior PD-1/PD-L1 therapy (radiographic progression within 6 months of discontinuing immunotherapy; immunotherapy does not need to be the immediate line of preceding therapy)
Cannot have received: Janus kinase inhibitor
No prior treatment with Janus kinase inhibitors
Lab requirements
Blood counts
Absolute neutrophil count ≥ 1.0×10^9/L; Platelet count ≥ 100×10^9/L; Hemoglobin level ≥ 8.5 g/dL; criteria must be met without erythropoietin dependency and without packed red blood cell transfusion within the last 2 weeks
Kidney function
Serum creatinine ≤ 2 mg/dL (or estimated creatinine clearance ≥ 30 mL/minute calculated by the Cockcroft Gault or Modification of Diet in Renal Disease formulas)
Liver function
Aspartate Aminotransferase and Alanine Aminotransferase ≤ 2.5 x upper limit of normal; Bilirubin ≤1.5 x upper limit of normal
Adequate organ and marrow function: * Absolute neutrophil count ≥ 1.0×10^9/L. * Platelet count ≥ 100×10^9/L. * Hemoglobin level ≥ 8.5 g/dL; criteria must be met without erythropoietin dependency and without packed red blood cell transfusion within the last 2 weeks. * Serum creatinine ≤ 2 mg/dL (or estimated creatinine clearance ≥ 30 mL/minute calculated by the Cockcroft Gault or Modification of Diet in Renal Disease formulas). * Aspartate Aminotransferase and Alanine Aminotransferase ≤ 2.5 x upper limit of normal. * Bilirubin ≤1.5 x upper limit of normal.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California, San Diego Moores Cancer Center · La Jolla, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07219576 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior Janus kinase inhibitor disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify